NCT06006403View on ClinicalTrials.gov

Safety and Efficacy of CD123-targeted CAR-NK for Relapsed/Refractory Acute Myeloid Leukemia or Blastic Plasmacytoid Dendritic Cell Neoplasm

PHASE1/PHASE2RecruitingINTERVENTIONAL
Enrollment

36

Participants

Timeline

Start Date

August 31, 2023

Primary Completion Date

December 31, 2025

Study Completion Date

August 31, 2026

Conditions
Acute Myeloid LeukemiaBlastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN)Relapse LeukemiaRefractory Leukemia
Interventions
BIOLOGICAL

CD123 targeted CAR-NK cells

Administration method: intravenous infusion； Subjects will receive conditioning therapy by Fludarabine and Cyclophosphamide before cell infusion.

Trial Locations (1)

Unknown

RECRUITING

Shanxi Bethune Hospital, Taiyuan

All Listed Sponsors
collaborator

Shanxi Bethune Hospital

OTHER

lead

Chongqing Precision Biotech Co., Ltd

INDUSTRY